<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">Besides HIV positivity, all factors used in our study to determine trial eligibility are known prognostic factors for survival. Hence, the patients enrolled in clinical trials are those with a favourable prognosis, resulting in approval of treatment algorithms fitted to their needs. For example, no changes in dose or schedule of MPT or VMP are approved according to age or performance status, although these regimens are accompanied by a high rate of grade 3â€“4 adverse events [
 <xref ref-type="bibr" rid="CR30">30</xref>, 
 <xref ref-type="bibr" rid="CR31">31</xref>]. A study on 502 non-transplant patients in US community practice showed no advantage of triplet combinations over the doublet regimen VD [
 <xref ref-type="bibr" rid="CR32">32</xref>], highlighting the need for adapted treatment algorithms for elderly and trial-ineligible patients.
</p>
